Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDURA XL vs FLOMAX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective alpha-1 adrenergic receptor antagonist; inhibits postsynaptic alpha-1 adrenoceptors in vascular smooth muscle and the prostate, causing vasodilation and relaxation of prostatic smooth muscle.
Selective antagonist of alpha-1A and alpha-1D adrenergic receptors in the prostate, bladder base, and bladder neck, leading to relaxation of smooth muscle and improved urinary flow.
Benign prostatic hyperplasia (FDA-approved),Hypertension (FDA-approved)
Treatment of signs and symptoms of benign prostatic hyperplasia (BPH),Off-label: adjunctive therapy for ureteral calculi expulsion
4 mg orally once daily, with breakfast. May titrate to 8 mg once daily based on response. Maximum dose: 8 mg daily.
0.4 mg orally once daily, approximately 30 minutes after the same meal each day. If no response after 2-4 weeks, may increase to 0.8 mg once daily.
15-22 hours in adults; terminal half-life is approximately 22 hours for extended-release formulation, allowing once-daily dosing. Half-life is prolonged in elderly and patients with hepatic impairment.
Terminal elimination half-life is approximately 14-15 hours (range 6-20 hours) in healthy adults, allowing once-daily dosing.
Extensively metabolized in the liver via CYP3A4 and CYP2D6; undergoes O-demethylation and hydroxylation.
Extensively metabolized in the liver via CYP3A4 and CYP2D6 enzymes.
Primarily hepatic metabolism via CYP3A4, with ~63% of the dose excreted in feces as metabolites and ~9% in urine as unchanged drug. Renal elimination of active drug is minimal (<1%).
Primarily hepatic metabolism (CYP3A4, CYP2D6) with <10% excreted unchanged in urine; fecal excretion accounts for ~76% of metabolites.
~98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
94-99% bound primarily to alpha-1 acid glycoprotein, with high affinity.
1.9-3.1 L/kg, indicating extensive distribution into tissues, including vascular smooth muscle.
Approximately 16 L/kg (or 16 L for an average 70 kg patient), indicating extensive tissue distribution.
Oral extended-release: ~85% relative to immediate-release formulation, with minimal first-pass metabolism. Food does not significantly affect absorption.
Oral bioavailability is approximately 90% (capsule) due to extensive absorption, with minimal first-pass metabolism.
No dose adjustment required for renal impairment (GFR ≥30 m L/min). For GFR <30 m L/min, use with caution; no specific dose recommendation available.
No adjustment required for GFR ≥10 m L/min; insufficient data for GFR <10 m L/min, use with caution.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh class A or B), start at 2 mg once daily and titrate cautiously.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Use with caution; consider starting at 0.4 mg once daily. Child-Pugh Class C: Contraindicated.
Safety and efficacy not established in pediatric patients; no recommended dosing.
Not approved for pediatric use; safety and efficacy not established.
Initiate at 2 mg once daily with breakfast; titrate slowly to avoid orthostatic hypotension. Monitor blood pressure closely.
Same dosing as adults; monitor for orthostatic hypotension and dizziness. Consider starting at 0.4 mg once daily.
None.
None.
Orthostatic hypotension and syncope, especially with first dose or dose increase,Priapism (rare),Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery,Hepatic impairment: dose adjustment may be needed
Orthostatic hypotension and syncope, especially upon initiation or dose increase,Intraoperative floppy iris syndrome (IFIS) during cataract surgery,Priapism (rare),Hepatic impairment,Consideration of prostate cancer before initiating therapy
Hypersensitivity to doxazosin or any component,Concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of hypotension
Hypersensitivity to tamsulosin hydrochloride or any component of the formulation,Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) in patients with moderate to severe hepatic impairment
Avoid grapefruit and grapefruit juice as they may increase doxazosin concentrations. No other significant food interactions known. Alcohol may exacerbate hypotensive effects.
Grapefruit juice may increase tamsulosin levels; avoid concurrent intake. High-fat meals can decrease absorption; administer 30 minutes after the same meal daily.
Pregnancy Category C. First trimester: No adequate studies; animal studies show increased fetal resorption and decreased fetal weight at doses 5 times the MRHD. Second and third trimesters: Potential for reduced placental perfusion due to alpha-blockade; avoid use unless benefit outweighs risk.
Tamsulosin is FDA Pregnancy Category B. Animal studies revealed no evidence of teratogenicity at doses up to 50 mg/kg/day in rats and 5 mg/kg/day in rabbits (approximately 50 and 30 times the human exposure). There are no adequate and well-controlled studies in pregnant women; use only if clearly needed. First trimester: no known increased risk of major malformations. Second/third trimester: no known specific fetal risks; however, alpha-blockers may cause hypotension in the mother, potentially affecting placental perfusion. No reports of teratogenic effects in humans.
Unknown if excreted in human milk; M/P ratio not available. Caution advised; use only if clearly needed.
Tamsulosin is excreted in rat milk at concentrations 20-fold higher than maternal plasma. No human data exist; M/P ratio is not established. Due to potential for adverse effects (e.g., hypotension) in the nursing infant, breastfeeding is generally not recommended. Discontinue drug or bottle-feed, considering importance of therapy to mother.
No specific dose adjustments established; pharmacokinetics may be altered due to increased plasma volume. Use lowest effective dose and monitor clinical response.
No specific pharmacokinetic studies during pregnancy. Dose adjustments are not routinely recommended; however, hypotension risk may be increased due to pregnancy-related hemodynamic changes. Use the lowest effective dose and monitor for maternal hypotension to avoid fetal compromise.
CARDURA XL (doxazosin extended-release) is an alpha-1 adrenergic blocker primarily used for benign prostatic hyperplasia (BPH). Its prolonged action reduces the risk of first-dose syncope compared to immediate-release. Do not crush or chew; swallow whole. Monitor blood pressure in patients also on antihypertensives due to additive hypotensive effects. Avoid use in patients with history of orthostatic hypotension or micturition syncope.
First-dose orthostatic hypotension is common; administer at bedtime. Avoid use in patients with history of cataract surgery due to intraoperative floppy iris syndrome (IFIS). Tamsulosin is not recommended for hypertension. Renal impairment does not require dose adjustment. Use caution with strong CYP3A4 inhibitors (e.g., ketoconazole) and PDE5 inhibitors (e.g., sildenafil) due to enhanced hypotensive effects.
Take exactly as prescribed, once daily with or without food. Swallow tablet whole, do not crush or chew.,Avoid grapefruit juice as it may alter drug levels.,Possible side effects include dizziness, fatigue, and nasal congestion. Rise slowly from sitting or lying to reduce fall risk.,May cause orthostatic hypotension especially after first dose or dose increase.,If you experience lightheadedness or fainting, contact your doctor.
Take this medication approximately 30 minutes after the same meal each day to maintain consistent absorption.,Avoid getting up too quickly from a sitting or lying position to minimize dizziness.,Inform your ophthalmologist about tamsulosin use before any cataract surgery due to risk of floppy iris syndrome.,Do not drive or operate heavy machinery until you know how this medication affects you.,If you miss a dose, skip it and take the next dose at the usual time; do not double the dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDURA XL vs FLOMAX, answered by our medical review team.
CARDURA XL is a Alpha-1 Blocker Antihypertensive that works by Selective alpha-1 adrenergic receptor antagonist; inhibits postsynaptic alpha-1 adrenoceptors in vascular smooth muscle and the prostate, causing vasodilation and relaxation of prostatic smooth muscle.. FLOMAX is a Alpha-1 Blocker that works by Selective antagonist of alpha-1A and alpha-1D adrenergic receptors in the prostate, bladder base, and bladder neck, leading to relaxation of smooth muscle and improved urinary flow.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDURA XL and FLOMAX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDURA XL is: 4 mg orally once daily, with breakfast. May titrate to 8 mg once daily based on response. Maximum dose: 8 mg daily.. The standard adult dose of FLOMAX is: 0.4 mg orally once daily, approximately 30 minutes after the same meal each day. If no response after 2-4 weeks, may increase to 0.8 mg once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDURA XL and FLOMAX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDURA XL is classified as Category C. Pregnancy Category C. First trimester: No adequate studies; animal studies show increased fetal resorption and decreased fetal weight at doses 5 times the MRHD. Second and third tr. FLOMAX is classified as Category C. Tamsulosin is FDA Pregnancy Category B. Animal studies revealed no evidence of teratogenicity at doses up to 50 mg/kg/day in rats and 5 mg/kg/day in rabbits (approximately 50 and 3. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.